Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

Rhea-AI Summary

Science 37 Holdings, Inc. launches a Patient Recruitment Solution to provide fully consented patients to sites, leveraging its Metasite™ technology. The new solution aims to accelerate enrollment, reduce site burden, and improve efficiency in patient recruitment.

Positive

• Science 37 introduces a stand-alone Patient Recruitment Solution to deliver fully consented patients to sites.
• Traditional central patient recruitment campaigns are inefficient due to unqualified referrals and lack of medical history.
• Science 37's Metasite™ reviews patients' medical records, consents them into studies, and manages run-in procedures remotely.
• The Company's recent merger with eMed will expand access to new patients and technology for enhanced enrollment processes.
• Science 37 holds a patent pending for its unique patient recruitment solution.

Negative

• None.

New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burden

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry’s leading Metasite^TM, today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.

While traditional central patient recruitment campaigns have proven to be effective in accelerating enrollment, they are fraught with inefficiencies. The majority of referred patients are not fully qualified, do not have a documented medical history, or are not fully informed regarding expectations for the study. Many sites don’t have adequate resources to follow up on all their referrals, and even when they can, very few patients ever make it to their first screening visit. Sometimes these patient referrals are even offered the ability to participate in competing studies.

Science 37 is leveraging its Metasite to not only recruit patients but also to acquire and review the patients’ full medical records and consent the patients into studies with oversight from Science 37 Primary Investigators. The Company also has the capability to manage many of the run-in procedures—from the comfort of the patient’s own home—that are often required to fully qualify a participant.

“We’ve been recruiting, qualifying, and consenting patients for 10 years as a Metasite,” said Erica Prowisor, SVP of Patient & Provider Networks at Science 37. “We empathize with sites on the complexity required to turn a referral into a consented participant. Today, we’re offering sponsors the opportunity to relieve sites of that burden, ensure their recruitment spend is more efficient, and meet their ultimate goal of accelerated enrollment.”

With its recent merger with eMed, Science 37 will dramatically expand its access to new patients and technology to further enhance its enrollment process. The Company also has a patent pending with respect to its solution to ensure it will continue to be one-of-a-kind.

About eMed

eMed is a telehealth and diagnostics company that develops a leading digital point-of-care platform designed for complete testing processes to be done at home. The company's platform provides verified test results and access to on-demand prescription treatment with same-day delivery, enabling consumers to easily get tested and receive expert healthcare guidance.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; The Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies/.

Media Inquiries

Science 37
pr@science37.com

FAQ

What did Science 37 announce?

Science 37 Holdings, Inc. announced the launch of a stand-alone Patient Recruitment Solution to provide fully consented patients to sites.

Why are traditional central patient recruitment campaigns considered inefficient?

Traditional central patient recruitment campaigns are inefficient due to unqualified referrals, lack of medical history, and patients not fully informed about study expectations.

How does Science 37's Metasite™ improve patient recruitment?

Science 37's Metasite™ reviews patients' medical records, consents them into studies, and manages run-in procedures remotely, reducing site burden.

What is the impact of Science 37's merger with eMed?

The merger with eMed will expand Science 37's access to new patients and technology, enhancing its enrollment processes.

Does Science 37 hold any patents related to patient recruitment?

Science 37 has a patent pending for its unique patient recruitment solution, ensuring its one-of-a-kind status.